Helius Medical Technologies, Inc. (HSDT) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024, for Helius Medical Technologies, Inc. (HSDT), a neurotechnology company developing the Portable Neuromodulation Stimulator (PoNS) device. The company operates in a single segment, selling devices directly to patients in the U.S. and to clinics in Canada. The filing includes a "Going Concern" warning due to an accumulated deficit of $164.1 million and continued operating losses.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $182,000 | $317,000 | $256,000 | $367,000 |
| Gross Profit | $64,000 | $76,000 | $72,000 | $61,000 |
| Net Loss | $(1,612,000) | $(4,128,000) | $(1,648,000) | $(4,142,000) |
| Operating Loss | $(3,270,000) | $(6,686,000) | $(3,219,000) | $(7,029,000) |
| Cash & Equivalents | $6,387,000 (as of June 30, 2024) | |||
| Working Capital | $6,584,000 (as of June 30, 2024) | |||
| Derivative Liability | $347,000 (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 29% year-over-year for Q2 ($182k vs $256k) and 14% for the six-month period ($317k vs $367k). The decline is attributed to the termination of the Patient Therapy Access Program (PTAP) in June 2023 and the end of temporary cash pay pricing in May 2024.
- Geographic Shift: U.S. product sales dropped significantly ($67k in Q2 2024 vs $175k in Q2 2023), while Canadian sales increased ($104k vs $69k).
- Non-Operating Gains: Net loss was significantly offset by a non-cash gain of $1.7 million in Q2 (and $2.9 million YTD) from the change in fair value of a derivative liability (warrants), driven by a decrease in the company's stock price.
- Capital Raise: In May 2024, the company completed a public offering raising approximately $5.5 million in net proceeds, improving liquidity.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased slightly year-over-year, while R&D expenses increased due to clinical trial activities for stroke and fall risk programs.
Outlook, Risks, and Management Commentary
- Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern within one year. They intend to fund operations through existing cash, product sales, and additional equity/debt financing.
- Nasdaq Compliance: The company received a notification on August 9, 2024, regarding non-compliance with the Nasdaq minimum bid price requirement ($1.00/share). They have until February 5, 2025, to regain compliance or face potential delisting.
- Reimbursement Strategy: The company is pursuing Medicare and commercial insurance coverage. CMS assigned HCPCS codes effective April 1, 2024, with final reimbursement rates expected in late August/early September 2024. Preliminary rates are significantly lower than current cash prices.
- Clinical Trials: Enrollment is ongoing for a registrational program to evaluate PoNS for chronic stroke, with FDA submission targeted for mid-to-late 2025.
- Manufacturing Transition: The company is transitioning manufacturing from Key Tronic Corporation to Minnetronix, Inc., expected to complete in Q3 2024.
Investor Verification Checklist
- Liquidity Runway: Verify if the $6.4 million cash balance is sufficient to fund operations through 2025 given the $4.1 million net loss for the first half of the year.
- Reimbursement Rates: Monitor the final CMS reimbursement rates for the PoNS controller and mouthpiece expected in late August 2024 to assess impact on U.S. revenue.
- Nasdaq Status: Track the stock price to ensure it meets the $1.00 minimum bid price requirement to avoid delisting.
- Derivative Liability: Understand that reported net loss is heavily influenced by non-cash gains/losses on warrant liabilities, which fluctuate with stock price.
- Customer Concentration: Note that three customers accounted for 97% of net product sales in Q2 2024, creating significant concentration risk.